Recent performance snapshot for UFP Technologies (UFPT)

UFP Technologies (UFPT) has drawn investor attention after recent share performance, with the stock near US$223.87 and mixed return figures over the past year, month and past 3 months.

The recent 7.2% three-month share price return contrasts with a one-year total shareholder return that declined 5.7%, while the five-year total shareholder return of 290.1% shows long-term investors have still seen strong compounding.

If you are weighing UFPT against other opportunities in the market, this can be a good moment to scan for companies with similar resilience and growth potential using our 21 top founder-led companies

With shares roughly flat year to date but an indicated intrinsic value and analyst target above the current US$223.87 price, you have to ask: Is UFPT offering a genuine entry point, or is the market already baking in future growth?

Preferred P/E of 25.2x: Is it justified?

On a P/E of 25.2x at a last close of $223.87, UFP Technologies screens as cheaper than many peers on earnings, although not cheap relative to its own fair-value benchmark.

The P/E ratio compares the current share price to earnings per share, so it effectively reflects how much investors are willing to pay for each dollar of earnings. For a medical equipment focused business with positive earnings and a history of profit growth, this is a widely used yardstick for how the market prices current and future profitability.

Against direct peers, UFPT looks supportive on this metric. The current 25.2x P/E is below the peer average of 39x, which suggests the stock is not pricing earnings as highly as comparable companies. Relative to the broader US Medical Equipment industry average of 25.3x, the stock is almost in line, pointing to a valuation that sits close to the sector norm. However, compared with the estimated fair P/E of 21.9x, the current multiple is higher, which signals a level that the market could reasonably move back toward if sentiment cools or earnings do not keep pace.

Result: Price-to-earnings of 25.2x (ABOUT RIGHT)

However, you also need to weigh risks such as UFPT’s relatively full 25.2x P/E compared with its fair-value benchmark and the potential for sentiment to cool.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another view: cash flows tell a different story

While the 25.2x P/E suggests UFPT is roughly in line with the US Medical Equipment sector, the SWS DCF model points in a different direction. With the stock around $223.87 and a future cash flow value estimate of $366.05, this approach frames UFPT as undervalued and raises the question of which signal you trust more.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out UFP Technologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on valuation and sentiment are hard to ignore, so act while the information is fresh and weigh both sides by checking the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your style even better, so keep hunting for ideas that truly match your checklist.

• Target companies that combine quality with a reasonable entry point by scanning 49 high quality undervalued stocks and seeing which stocks currently align with your expectations.
• Prioritize capital preservation and sleep easier at night by filtering for 64 resilient stocks with low risk scores that may better suit a more cautious approach.
• Spot companies that the market might be overlooking by running the screener containing 22 high quality undiscovered gems and seeing which stories are still off most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.